Wilkins, A. (2017). Cerebellar dysfunction in multiple sclerosis. *Frontiers in Neurology, 8*, [312].
https://doi.org/10.3389/fneur.2017.00312

Publisher's PDF, also known as Version of record
License (if available):
CC BY
Link to published version (if available):
10.3389/fneur.2017.00312

Link to publication record in Explore Bristol Research
PDF-document

This is the final published version of the article (version of record). It first appeared online via Frontiers in Neurology at http://journal.frontiersin.org/article/10.3389/fneur.2017.00312/full#h8. Please refer to any applicable terms of use of the publisher.

**University of Bristol - Explore Bristol Research**

**General rights**

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/
Cerebellar Dysfunction in Multiple Sclerosis

Alastair Wilkins*

MS and Stem Cell Group, University of Bristol, Learning and Research, Southmead Hospital, Bristol, United Kingdom

Multiple sclerosis (MS) commonly affects the cerebellum causing acute and chronic symptoms. Cerebellar signs contribute significantly to clinical disability, and symptoms such as tremor, ataxia, and dysarthria are particularly difficult to treat. Increasing knowledge concerning the pathophysiology of cerebellar disease in MS from human postmortem studies, experimental models, and clinical trials has raised the hope that cerebellar symptoms will be better treated in the future.

Keywords: multiple sclerosis, demyelinating diseases, ataxia, cerebellar diseases, purkinje cells

INTRODUCTION TO MULTIPLE SCLEROSIS (MS)

Multiple sclerosis is an inflammatory disease of the central nervous system of unknown etiology. Typically patients have an initial relapsing and remitting course [relapsing remitting MS (RRMS)] followed by, in the majority of case, secondary progressive MS (SPMS) during which patients develop slow, insidious accumulation of disability (1). A small percentage of patients with MS have progressive disability from onset [primary progressive MS (PPMS)]. Despite extensive research and increasing knowledge of pathophysiological mechanisms, there is still no cure for the disease. Significant advances in therapeutics have occurred, and novel therapies, including natalizumab, alemtuzumab, fingolimod, and dimethyl fumarate have important disease-modifying effects (2).

The cerebellum and its efferent and afferent pathways are commonly affected in MS; and cerebellar ataxia is a common symptom of the disease, particularly in progressive disease (3, 4). Despite affecting the entire central nervous system, there are aspects of cerebellar involvement in MS that warrant specific attention and may give important insights into potential mechanisms and treatments for progressive disease. Within this review clinical aspects, pathological changes, monitoring of cerebellar changes in MS, and treatments for cerebellar disease will be discussed. In addition, various experimental models of cerebellar inflammation will be reviewed and how they may inform on future potential therapies.

CLINICAL FEATURES OF CEREBELLAR DYSFUNCTION IN MS

Coordination problems are common in MS and occur predominantly due to pathology within the cerebellum itself or impairment in cerebellar connections, including proprioceptive afferent inputs. Patients with MS may present with either acute cerebellar dysfunction relating to acute relapse or chronic cerebellar problems in progressive disease. Cerebellar pathology may lead to limb, gait, and truncal ataxia, dependent on precise lesional site, as well as other cerebellar features such as gaze-evoked nystagmus, dysarthria, and tremor.

Involvement of the cerebellum and brainstem connections occurs during MS relapse not infrequently. Cerebellar relapse at disease onset also seems to be associated with increased risk of cerebellar involvement during subsequent relapse (5). Multivariate analyses have suggested that involvement of the cerebellum at onset of the disease is associated with worse prognosis [shorter
time to expanded disability status scale (EDSS) score 6] (6). In a recent database study of approximately 15,000 patients who experienced a total of nearly 50,000 relapses, cerebellar relapses accounted for approximately 10% of all relapses; being more frequent in men and in those with longer duration of disease (7). Cerebellar/brainstem relapses are also associated with poor relapse recovery which, in itself, is associated with earlier onset of progressive disease (8).

In patients with established MS, ataxia is thought to occur in about 80%, with symptoms particularly prevalent in those with progressive disease (3, 4). MS tremor is thought to arise predominantly as a consequence of cerebellar and/or thalamic disease (9). Tremor may affect limbs, trunk, vocal cords, and head (titubation). Intention and postural tremors are the commonest types, although rest and rubral tremors occur rarely (10). Although significantly disabling, severe tremor is a relatively rare consequence of MS, occurring in 3% of patients in one study (11). Severe tremor in this study was associated with indicators of global disability, such as high EDSS. The pathophysiology of MS tremor is complex and likely to involve cerebellar connections, as well as cortical and basal ganglia connections. A pure cerebellar syndrome (in the absence of involvement of other parts of the central nervous system) should warrant the search for an alternative explanation, such as a metabolic disorder or an inherited cerebellar disorder. Gait ataxia is thought to arise predominantly due to damage to the anterior lobe of the cerebellum (12). Cerebellar dysartria appears uncommonly at disease onset but is common in those with advanced secondary progressive disease. Paroxysmal symptoms of MS are relatively infrequent, and paroxysmal dysartria with ataxia has been reported in MS and is thought to occur due to midbrain pathology (13, 14).

The intriguing role of the cerebellum in cognitive processing is a subject in intense research, and there is some suggestion that involvement of the cerebellum may be linked to defects in cognitive processes in MS (15). Injury to the cerebellum (from whatever cause) has been linked to deficits in verbal fluency, working memory, and attention, as well as executive dysfunction (16). Interestingly, the cognitive profile of MS patients with cerebellar lesions differs to those without cerebellar involvement (17). Reduced total cerebellar volume scores on magnetic resonance imaging (MRI) are associated with worse performance on cognitive tests (15). Specifically, volume loss of the posterior–inferior cerebellum is associated with poor cognitive function, whereas volume loss to anterior cerebellum is associated with motor dysfunction (12).

In summary, cerebellar dysfunction is a feature of both RRMS and progressive MS leading to a range of neurological manifestations. In general, involvement of the cerebellum is linked to increased disability and worse prognosis, which, given the important role of cerebellar connections in motor control, is perhaps not surprising.

**CEREBELLAR PATHOLOGY IN MS**

Cerebellar white matter lesions are well described in the literature and often apparent on MRI scans of patients with MS. Cerebellar peduncles are common lesional sites. Demyelination commonly occurs in cerebellar white matter (Figure 1). In addition, observations concerning gray matter demyelination in cerebral cortex has led to studies evaluating gray matter disease in the cerebellum (18, 19). Indeed, the cerebellar cortex appears a major site for demyelination with one study reporting 38.7% of the cerebellar cortex being affected in a cohort of PPMS and SPMS patients (20). Interestingly, in this study, the majority of gray matter lesions appeared independent of white matter lesions, with some tissue blocks showing very extensive gray matter demyelination in the near absence of underlying white matter disease. Cerebellar cortical lesions are typically classified as leukocortical (extending from white matter into adjacent gray matter); intracortical (purely gray matter) arising around inflamed veins and venules; and subpial lesions that are “band-like” and parallel to the meningeal surface (20). The latter are abundant in patients with progressive MS. Observations concerning the relationship of subpial demyelination and meningeal inflammation have been suggested a possible driver for neurodegenerative processes in progressive MS, although causative proof is needed (21).

Neuronal pathology in the MS cerebellum is less well defined. The study by Kutzelnigg et al. (mentioned above) showed neuronal pathology with some reductions in Purkinje cell density in lesions (compared to control) (20). No significant reductions in Purkinje cell densities were seen in non-lesional cerebellar gray matter. Our own study confirmed these observations and also showed changes in neurofilament phosphorylation states in Purkinje cells (22). We noted abnormal neurofilament phosphorylation with loss of dephosphorylated neurofilaments and increased expression of hyperphosphorylated neurofilaments. In addition, axonal spheroids (representing transection of the Purkinje cell axon) were note within leukocortical lesions, indicating significant Purkinje cell pathology within the MS cerebellum. Alterations in neurofilament phosphorylation states and

---

**FIGURE 1** | Proteolipid protein staining of human cerebellum of a patient with multiple sclerosis showing extensive white matter demyelination (red), which extends into the gray matter.
axonal transection are reported within cerebral white matter (23). In a further study of MS cerebellum, we showed reductions in neuronal and myelin markers with evidence for increased lipid peroxidation end products (end products of oxidative injury to polyunsaturated fatty acids found in cell membranes) (24). We also found elevation in superoxide dismutase enzyme expression in MS cerebellum (compared to control) but a relative lack of other antioxidant enzyme expression, suggesting a possible mechanism for the extensive oxidative stress-related injury seen.

Other changes in Purkinje cell phenotype have been documented in MS, notably changes in ion channel expression and receptor profiles. The Na,1.8 sensory neuron-specific sodium channel is normally expressed at very low levels in Purkinje cells, but its expression is markedly upregulated in MS (25). In addition, annexin light chain (p11) that facilitates the functional expression of this ion channel is also upregulated in Purkinje cells (26). In experimental models, aberrant expression of Na,1.8 in Purkinje cells causes significant abnormalities of firing patterns of these cells (27, 28).

The interesting phenomenon of Purkinje cell heterokaryon formation has been noted to occur in MS cerebellum (29). This process appears to occur almost exclusively in Purkinje cells within the central nervous system and denotes the appearance of binucleated cells. Binucleation is thought to occur by cell fusion, a process by which the nucleus of a non-Purkinje cell is donated and integrates with the Purkinje cell (30). The commonest type of “donor” cell in experimental paradigms of cell fusion are bone marrow-derived cells, and researchers have postulated the donation of a foreign nucleus to the Purkinje cell may be a mechanism of protecting the cell from injury, since expression of donor cell genes occurs. In MS, binucleated Purkinje cells are significantly increased compared to control, suggesting a possible adaptive process occurring in response to the disease.

There still remains much to be understood about the pathology of the cerebellum in MS; for instance, there is a paucity of information on processes occurring in the molecular or granular layers; and histopathological correlates of cerebellar symptoms are lacking. Many of the pathological findings in MS cerebellum are shared with other neurological conditions affecting the cerebellum (e.g., neurofilament changes; Purkinje cell injury). Understanding which pathological features are specific to MS may help design future therapies. Furthermore, understanding why cerebellar pathology is linked to a worse prognosis in the disease may help design therapies for cerebellar dysfunction in MS.

**MONITORING CEREBELLAR DISEASE IN MS**

The major disability rating scales used in MS incorporate estimations of ataxia to a variable degree. These scales are used to provide a semiquantitative description of disability in the disease and remain prominent outcome measures of new therapies in clinical trials. The EDSS is the most commonly used disability scale in MS trials, and its quantification of disability relies heavily on motor dysfunction (31). As part of the grading, disturbances of functional systems (FS), such as visual function or bowel and bladder function, are assessed and can contribute to the overall score attributed. The cerebellar system is one of the FS tested, and increasing levels of ataxia may contribute to the overall EDSS level. Other scales also incorporate cerebellar function. For instance, the multiple sclerosis functional composite has a 9-hole peg test as one of the three tests involved, which relies heavily on the integrity of cerebellar functioning (32). The relevance of specific ataxia ratings scales has not been studied in MS in detail. Primarily these scales have been developed for assessment of “pure” cerebellar or spinocerebellar syndromes, typically the inherited ataxias.

Magnetic resonance imaging studies have confirmed extensive cerebellar involvement in both RRMS and progressive MS (33, 34). The revised McDonald criteria for the diagnosis of MS recognize infratentorial regions of the central nervous system to be a typical lesional site in MS (35). Recent diffusion-weighted MRI (DWI) techniques using a diffusion tensor model have changes in white matter tracts in MS, notably cerebellar peduncles. One study revealed abnormalities in tractography signals within the superior cerebellar peduncle, which correlated with upper limb dysfunction in patients with PPMS (36). Indeed, the presence of T2 lesions within cerebellar peduncles on MRI was associated with cerebellar and ambulatory symptoms in a large imaging study (37). As stated above, cerebellar gray matter disease may be extensive in pathological samples. A combined MRI and posturography study showed that gray matter atrophy of the superior lobules of the cerebellum (IV, V, VI), and lobules VIII correlated with worse posturometric values (38). Magnetic resonance spectroscopy (MRS) has been used to study neuronal markers, typically N-acetyl aspartate, in patients with MS looking for evidence of neuronal/axonal loss in progressive disease. Persistent cerebellar dysfunction has been linked with MRS markers of axonal loss in the cerebellum of patients with progressive MS (39).

Other cerebellar monitoring techniques, such as saccadic movements using eye-tracking technology, may become useful methods of monitoring cerebellar disease in MS (40). Defining suitable measures of cerebellar disease burden may be of importance in the future should disease modifying or symptomatic therapies be developed for specific cerebellar issues related to MS.

**EXPERIMENTAL MODELS OF CEREBELLAR INFLAMMATION AND NEURODEGENERATION**

The most well-established animal model for MS is experimental autoimmune encephalomyelitis (EAE). It is, however, not without its limitations, since many of the features of MS fail to be replicated in the model. Cerebellar inflammation occurs commonly during the course of EAE. The specific mode of inducing EAE may influence the predilection for cerebellar involvement (41). Purkinje cell dysfunction has been shown to occur in EAE with reduced synaptic function (42). Loss of Purkinje cell and gray matter pathology have also been documented in EAE (43).
Several models of dysmyelination and non-immune myelin loss have been studied. A model of slow, progressive myelin loss in a naturally occurring rat mutant is associated with extensive axonal changes (spheroid formation and neurofilament dephosphorylation) within the cerebellum (44).

Ion channel abnormalities in EAE have been noted for some time and form the basis for ongoing trials of sodium channel blockers in MS. Persistent sodium ion influx into the axon (associated with failure of ATP-dependent sodium/potassium exchange mechanisms in the context of reduced energy availability) leads to reversal of the sodium/calcium exchanger and thus excess intra-axonal calcium ions accumulate. Sodium channel blockade certainly appears to ameliorate axonal injury in EAE, but so far human trials have been less impressive (45). Indeed, ion channel abnormalities in Purkinje cells of mice affected by EAE have been documented, with aberrant expression of Na1.8 channels causing alteration of electrophysiological properties of Purkinje cells (28).

The finding of cell fusion in MS cerebellum noted above has been postulated as a potential mechanism for Purkinje cell rescue in various neurological diseases. Transplantation of human mesenchymal stem cells into mice which have subsequently been given EAE leads to expression of human markers within the cerebellum of these mice, suggesting that in EAE cell fusion occurs (46). Whether this leads to some form of neuroprotection in the cerebellum is unclear.

**TREATMENTS FOR CEREBELLAR DISEASE IN MS**

Treatments for MS fall into the categories of symptomatic treatments for established symptoms and disease-modifying therapies (DMTs), which aim to reduce the burden of disease. The design of DMT trials has not sought to determine whether these drugs improve cerebellar function specifically. The majority of trials have used reduction in annualized relapse rates and EDSS scores (as a marker of disability progression). As mentioned earlier, the EDSS does have cerebellar function as part of the assessment, but its utility in picking out specific effects of drugs on cerebellar function is limited. However, cerebellar relapses are associated with an increased risk of disability accrual (relative to some other relapse types, such as sensory) (47). Thus, reducing relapses by DMTs is likely to reduce the burden of cerebellar disease in the long term. Interestingly, analysis of an alemtuzumab trial (CAMSS223 versus beta-interferon) demonstrated improvements in the cerebellar FS score of the EDSS (48).

Non-pharmacological approaches to MS ataxia are commonly employed, of which physiotherapy regimens are the most widely accepted. Balance-specific exercises involving somatosensory and motor strategy facilitation are generally employed to varying degrees (49). Improving core stability in patients with balance problems may be effective, and lumbar stabilization exercises (which improve core trunk muscles, leading to effects on postural control, ambulation, and skilled motor function) are often incorporated into MS rehabilitation programs (50).

In addition, task-oriented training enhances ambulation and postural control in MS patients due to the promotion of motor learning (51). In general, combinations of these physiotherapy approaches are thought to be most beneficial (52).

Pharmacological approaches to improving ataxic symptoms are generally disappointing, and newer therapies are needed. The most recent Cochrane review of treatments for ataxia in MS (which reviewed six randomized placebo-controlled trials) concluded that absolute and comparative efficacy and tolerability of pharmacotherapies are poorly documented and no recommendations could be made (53). Small open label studies or case reports have suggested benefits for a range of drugs for the treatment of tremor. Isoniazid, propranolol, and levetiracetam have been studied, although the data on their use are not convincing (the number of patients involved in these trials was generally very low, and limited conclusions could be drawn) and they are not widely used (54–59). Several randomized controlled trials of cannabis extracts have concluded that cannabinoids appear to have no beneficial effect on MS tremor (60–62). Paroxysmal ataxia and dysarthria have been reported in MS, albeit rarely, and there is some suggestion that they may respond to carbamazepine, in a similar way to other paroxysmal symptoms of MS, such as tonic spasm (63).

The majority of reports of stereotactic surgery in MS tremor have targeted thalamic structures with variable results (64, 65). In the Cochrane review, one neurosurgical study of thalamotomy versus thalamic stimulation was included (53). Tremor was abolished by both thalamotomy and thalamic stimulation in all patients immediately postsurgery (66). However, tremor returned in almost all MS patients after 6 months (albeit of less severity than preoperative levels) and general disability scores were unchanged. The short-lived nature of the response is seen in other studies of surgical treatments of MS tremor (67). Improvement in quality of life measures following thalamic stimulation, including improvement in ability to feed oneself, has been demonstrated in selected cases (68).

There is a great need to improve therapeutic options for symptomatic treatments of cerebellar symptoms and to provide neuroprotection within the cerebellum. The design of trials aimed specifically at cerebellar protection in MS will be challenging due to the paucity of good outcome measures, although improvements in imaging techniques will help. Refinedms in neurosurgical techniques may help patients with severe ataxic tremors. Increased understanding of the pathophysiology of cerebellar disease in MS will aid the search for new drug therapies. A number of trials are now being pioneered specifically aimed at slowing disease progression. Newer therapies, such a stem cell therapies, are being developed. The observation of Purkinje cell fusion as a potential neurorestorative mechanism makes the prospect of stem cell treatments for MS cerebellar disease particularly attractive.

**AUTHOR CONTRIBUTIONS**

The author confirms being the sole contributor of this work and approved it for publication.
REFERENCES

1. Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sorensen PS, Thompson AJ, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. *Neurology* (2014) 83(3):278–86. doi:10.1212/WEU.0000000000000560
2. Kalincik T, Brown JW, Robertson N, Willis M, Scolding N, Rice CM, et al. Treatment effectiveness of alentuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. *Lancet Neurol* (2017) 16(4):271–81. doi:10.1016/S1474-4422(17)30007-8
3. Kurtzke JF, Beebe GW, Nagler B, Nefzger MD, Auth TL, Kurland LT. Studies on the natural history of multiple sclerosis. *V. Long-term survival in young men. Arch Neurol* (1970) 23(3):215–25. doi:10.1001/archneur.1970.00480210025003
4. Swinger RJ, Compston DA. The morbidity of multiple sclerosis. *Q J Med* (1992) 83(300):325–37.
5. Mowry EM, Deen S, Malikova I, Pelletier J, Bacchetti P, Waubant E. The onset location of multiple sclerosis predicts the location of subsequent relapses. *J Neurol Neurosurg Psychiatry* (2008) 80(4):400–3. doi:10.1136/jnnp.2008.157305
6. Weishenker BG, Rice GP, Noseworthy JH, Carriere W, Baskerville J, Ebers GC. The natural history of multiple sclerosis: a geographically based study. *Multivariate analysis of predictive factors and models of outcome. Brain* (1991) 114(Pt 2):1045–56. doi:10.1093/brain/114.2.1057
7. Kalincik T, Buzzard K, Jokubaitis V, Trojano M, Duquette P, Izquierdo G, et al. Poor early relapse recovery affects onset of progressive disease course in multiple sclerosis. *Neurology* (2015) 85(6):722–9. doi:10.1212/WEU.000000000001856
8. Koch M, Mostert J, Heersema D, De Keyser J. Tremor in multiple sclerosis. *J Neurol Neurosurg Psychiatry* (2007) 254(2):133–45. doi:10.1136/00001756-20070026-00007
9. Alusi SH, Worthington J, Glickman S, Bain PG. A study of tremor in multiple sclerosis. *Brain* (2001) 124(Pt 4):720–30. doi:10.1093/brain/124.4.720
10. Pittock SJ, McClelland RL, Mayr WT, Rodriguez M, Matsumoto JY. Prevalence of tremor in multiple sclerosis and associated disability in the Olmsted County population. *Mov Disord* (2000) 15(12):1842–5. doi:10.1002/mds.20227
11. D’Ambrosio A, Pagani E, Riccittelli GC, Colombo B, Rodrigher M, Falini A, et al. Cerebellar contribution to motor and cognitive performance in multiple sclerosis: an MRI sub-regional volumetric analysis. *Mult Scler* (2016). doi:10.1177/1352458516674667
12. Blanco Y, Compta Y, Graus F, Saiz A. Midbrain lesions and paroxysmal dysarthria in multiple sclerosis. *Brain* (2008) 13(5):694–7. doi:10.1097/01.wna.0000321061.59104.6e
13. Valentinio P, Nistico R, Pirritano D, Bilotti G, Del Giudice F, Sturmiolo M, et al. Lamotrigine therapy for paroxysmal dysarthria caused by multiple sclerosis. *Brain Res* (2010) 1352458507087846
14. Weier K, Till C, Fonov V, Yeh EA, Arnold DL, Banwell B, et al. Contribution of the cerebellum to cognitive performance in children and adolescents with multiple sclerosis. *Mult Scler* (2016) 22(5):599–607. doi:10.1177/1352458515599132
15. Tedesco AM, Chiricozzi FR, Clauss I, Lupo M, Molinari M, Leggio MG. The cerebellar cognitive profile. *Brain* (2011) 134(Pt 12):3672–86. doi:10.1093/brain/awr266
16. Weier K, Penner IK, Magon S, Aman M, Naegelin Y, Andelova M, et al. Cerebellar abnormalities contribute to disability including cognitive impairment in multiple sclerosis. *PLoS One* (2014) 9(1):e86916. doi:10.1371/journal.pone.0086916
17. Petersen JW, Bo L, Mörk S, Chang A, Trapp BD. Transacted neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. *Ann Neurol* (2001) 50(3):389–400. doi:10.1002/ana.11123
18. Lucchinetti CF, Popescu BF, Bunyan RF, Moll NM, Roemer SF, Lassmann H, et al. Inflammatory cortical demyelination in early multiple sclerosis. *N Engl J Med* (2011) 365(23):2188–97. doi:10.1056/NEJMoa1100648
19. Kutzelnigg A, Faber-Rod JC, Bauer J, Lucchinetti CF, Sorensen PS, Laursen H, et al. Widespread demyelination in the cerebellar cortex in multiple sclerosis. *Brain Pathol* (2007) 17(1):38–44. doi:10.1111/j.1528-1347.2006.00041.x
20. Mainero C, Louapre C. Meningeal inflammation in multiple sclerosis: the key to the origin of cortical lesions? *Neurology* (2015) 85(1):12–3. doi:10.1212/WEU.000000000001586
21. Redondo J, Kemp K, Hares K, Rice C, Scolding N, Wilkins A. Purkinje cell pathology and loss in multiple sclerosis cerebellum. *Brain Pathol* (2015) 25(6):692–700. doi:10.1111/bpa.12230
22. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bö L. Axonal transaction in the lesions of multiple sclerosis. *N Engl J Med* (1998) 338(5):278–85. doi:10.1056/NEJM199801293380502
23. Kemp K, Redondo J, Hares K, Rice C, Scolding N, Wilkins A. Oxidative injury in multiple sclerosis cerebellar grey matter. *Brain Res* (2016) 1642:452–60. doi:10.1016/j.brainres.2016.04.027
24. Black JA, Dib-Hajj S, Baker D, Newcombe J, Cuzner ML, Waxman SG. Sensory neuron-specific sodium channel SNS is abnormally expressed in the brains of mice with experimental allergic encephalomyelitis and humans with multiple sclerosis. *Proc Natl Acad Sci U S A* (2000) 97(21):11598–602. doi:10.1073/pnas.97.21.11598
25. Cranner MJ, Lo AC, Black JA, Baker D, Newcombe J, Cuzner ML, et al. Annexin II/p11 is up-regulated in Purkinje cells in EAE and MS. *Neuroreport* (2003) 14(4):555–8. doi:10.1079/0959-4644(2003)14(4)555
26. Renganathan M, Gelderblom M, Black JA, Waxman SG. Expression of Nav1.8 sodium channels perturbs the firing patterns of cerebellar Purkinje cells. *Brain Res* (2003) 959(2):235–42. doi:10.1016/S0006-8993(02)07350-2
27. Shields SD, Cheng X, Gasser A, Saab CY, Tyrell L, Eastman EM, et al. A channelopathy contributes to cerebellar dysfunction in a model of multiple sclerosis. *Brain Res* (2012) 124(2):186–94. doi:10.1016/j.brainres.2012.02.012
28. Kemp K, Gay E, Wilkins A, Scolding N. Purkinje cell fusion and binucleate heterokaryon formation in multiple sclerosis cerebellum. *Brain* (2012) 135(Pt 10):2962–72. doi:10.1093/brain/aws226
29. Kemp K, Wilkins A, Scolding N. Cell fusion in the brain: two cells forward, one cell back. *Acta Neuropathol* (2014) 128(5):629–38. doi:10.1007/s00401-014-1303-1
30. Lucchinetti CF, Faber-Rod JC, Bauer J, Lassmann H. Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axon loss. *Brain* (1995) 118(6):1583–92. doi:10.1093/brain/118.6.1583
40. Moroso A, Rueu A, Deloire M, Lamargue-Hamel D, Cubizolle S, Charré-Morin J, et al. Cerebellar assessment in early multiple sclerosis. *Cerebellum* (2017) 16(1):607–11. doi:10.1007/s12311-016-0831-8

41. Kuerten S, Kostova-Bales DA, Frenzel LP, Tigno JT, Tary-Lehmann M, Angelov DN, et al. MP4- and MOG-35-55-induced EAE in C57BL/6 mice differentially targets brain, spinal cord and cerebellum. *J Neuroimmunol* (2007) 189(1–2):31–40. doi:10.1016/j.jneuroim.2007.06.016

42. Mandolesi G, Grasselli G, Musella A, Gentile A, Musumeci G, Sepham M, et al. GABAergic signaling and connectivity on Purkinje cells are impaired in experimental autoimmune encephalomyelitis. *Neurobiol Dis* (2012) 48(3):637–51. doi:10.1016/j.nbd.2012.02.005

43. MacKenzie-Graham A, Tiwari-Woodruff SK, Sharma G, Aguilar C, Vo KT, Strickland LV, et al. Purkinje cell loss in experimental autoimmune encephalomyelitis. *Neuroimage* (2009) 48(4):637–51. doi:10.1016/j.neuroimage.2009.06.073

44. Wilkins A, Kondo Y, Song J, Liu S, Compston A, Black JA, et al. Slowly progressive axonal degeneration in a rat model of chronic, nonimmune-mediated demyelination. *J Neuropathol Exp Neurol* (2010) 69(12):1256–69. doi:10.1097/NEN.0b013e3181f7c3f1

45. Kapoor R, Furby J, Hayton T, Smith KJ, Altmann DR, Brenner R, et al. Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial. *Lancet Neurol* (2010) 9(7):681–8. doi:10.1016/S1474-4422(10)70131-9

46. Kemp K, Gordon D, Wraith DC, Mallam E, Hartfield E, Uney J, et al. Fusion between human mesenchymal stem cells and rodent cerebellar Purkinje cells. *Neuropathol Appl Neurobiol* (2011) 37(2):166–78. doi:10.1111/j.1356-2990.2010.01122.x

47. Stewart T, Spelman T, Havrdova E, Horakova D, Trojanu M, Izquierdo G, et al. Contribution of different relapse phenotypes to disability in multiple sclerosis. *Mult Scler* (2017) 23(2):266–76. doi:10.1177/1352458516643392

48. Fox EJ, Wynn D, Coles AJ, Palmer J, Margolin DH; CAMMS223 Investigators. A task-oriented circuit training in multiple sclerosis: a feasibility study. *Mult Scler* (2017) 23(11):1377–84. doi:10.1177/1352458510378126

49. Angelov DN, et al. MP4- and MOG:35-55-induced EAE in C57BL/6 mice: contribution of different relapse phenotypes to disability in multiple sclerosis. *Mult Scler* (2017) 23(11):1377–84. doi:10.1177/1352458510378126

50. Freeman JA, Gear M, Pauli A, Cowan P, Finnigan C, Hunter H, et al. The effect of core stability training on balance and mobility in ambulant individuals with multiple sclerosis: a multi-centre series of single case studies. *Mult Scler* (2010) 16(11):1377–84. doi:10.1177/1352458510378126

51. Straudi S, Martinuzzi C, Pavaralle C, Sabbagh-Charabati A, Benedetti MG, Foti C, et al. A task-oriented circuit training in multiple sclerosis: a feasibility study. *BMC Neurol* (2014) 14:124. doi:10.1186/1471-2377-14-124

52. Salci Y, Fil A, Armutlu K, Yildiz FG, Kurne A, Aksoy S, et al. Effects of different exercise modalities on ataxia in multiple sclerosis patients: a randomized controlled study. *Disabil Rehabil* (2016) 1–7. doi:10.1080/09638288.2016.1236411

53. Mills RJ, Yap L, Young CA. Treatment for ataxia in multiple sclerosis. *Cochrane Database Syst Rev* (2007) (1). doi:10.1002/14651858.CD005029.pub2

54. Sabra AF, Hallett M, Sudasky L, Mullally W. Treatment of action tremor in multiple sclerosis with isoniadiaz. *Neurology* (1982) 32(8):912–3. doi:10.1212/00005390-198208000-00040

55. Duquette P, Pletsch J, du Souich P. Isoniazid for tremor in multiple sclerosis: a controlled trial. *Neurology* (1985) 35(12):1772–3. doi:10.1212/00005390-198512000-00040

56. Morrow J, McDowell H, Ritchie C, Patterson V. Isoniazid and action tremor in multiple sclerosis. *J Neurol Neurosurg Psychiatry* (1985) 48(3):282–3. doi:10.1136/jnnp.48.3.282

57. Francis DA, Grundy D, Heron JR. The response to isoniazid of action tremor in multiple sclerosis and its assessment using polarised light goniometry. *J Neurol Neurosurg Psychiatry* (1986) 49(1):87–9. doi:10.1136/jnnp.49.1.87

58. Koller WC. Pharmacologic trials in the treatment of cerebellar tremor. *Arch Neurol* (1984) 41(3):280–1. doi:10.1001/archneur.1984.04050150058017

59. Feps P, D’hooghe MB, Nagels G, Helsen WF. The effect of levetiracetam on tremor severity and functionality in patients with multiple sclerosis. *Mult Scler* (2009) 15(3):571–8. doi:10.1177/1352458508099142

60. Zajicek J, Fox P, Sanders H, Wright D, Vickyery J, Nunn A, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. *Lancet* (2003) 362(9395):1517–26. doi:10.1016/S0140-6736(03)14738-1

61. Fox P, Bain PG, Glickman S, Carroll C, Zajicek J. The effect of cannabinoids on tremor in patients with multiple sclerosis. *Neurology* (2004) 62:1105–9. doi:10.1212/01.WNL.0000182023.67138.3E

62. Wade DT, Makela P, Robson P, House B, Bateman C. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. *Mult Scler* (2004) 10(4):434–41. doi:10.1177/135245850401002010

63. Twomey JA, Espir ML. Paroxysmal symptoms as the first manifestations of multiple sclerosis. *J Neurol Neurosurg Psychiatry* (1980) 43(4):296–304. doi:10.1136/jnnp.43.4.296

64. Yap L, Koyjialis A, Varma TR. Stereotactic neurosurgery for disabling tremors in multiple sclerosis: thalamotomy or deep brain stimulation? *Br J Neurosurg* (2004) 18(1):34–24. doi:10.1080/02688690701544002

65. Timmermann L, Deuschl G, Fogel W, Hilker R, Kupsch A, Lange M, et al. [Deep brain stimulation for tremor in multiple sclerosis: consensus recommendations of the German Deep Brain Stimulation Association]. *Nervenarzt* (2009) 80(6):673–7. doi:10.1016/j.kes.2009.06.025

66. Schuurman PR, Bosch DA, Bosson P, Bonsel GJ, van Someren El, de Bie RM, et al. A comparison of continuous thalamic stimulation and thalamotomy for suppression of severe tremor. *Neurol Arch* (1986) 49(1):87–9. doi:10.1136/jnnp.49.1.87

67. Hassan A, Ahsakog J, Rodriguez M, Matsumoto J, Surgical therapy for multiple sclerosis tremor: a 12-year follow-up study. *Eur J Neurol* (2012) 19(5):764–8. doi:10.1111/j.1468-1331.2011.03626.x

68. Zakaria R, Vajramani G, Westmoreland L, Fletcher N, Eldridge P, Alusi S, et al. Tremor reduction and quality of life after deep brain stimulation for multiple sclerosis-associated tremor. *Acta Neurochir* (2013) 155(12):2359–64. doi:10.1007/s00701-013-1848-0

Conflict of Interest Statement: The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.